BETAHISTINE GxP betahistine dihydrochloride 16 mg tablets blister packs

Riik: Austraalia

keel: inglise

Allikas: Department of Health (Therapeutic Goods Administration)

Osta kohe

Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
26-11-2017

Toimeaine:

betahistine dihydrochloride, Quantity: 16 mg

Saadav alates:

Arrotex Pharmaceuticals Pty Ltd

INN (Rahvusvaheline Nimetus):

betahistine dihydrochloride

Ravimvorm:

Tablet, uncoated

Koostis:

Excipient Ingredients: purified talc; mannitol; microcrystalline cellulose; citric acid; colloidal anhydrous silica

Manustamisviis:

Oral

Ühikuid pakis:

10 tablets, 30 tablets, 60 tablets, 100 tablets, 25 tablets

Retsepti tüüp:

(S4) Prescription Only Medicine

Näidustused:

Meniere's Syndrome as defined by the following core symptoms: vertigo (with nausea/vomiting), hearing loss (hardness of hearing) and tinnitus.

Toote kokkuvõte:

Visual Identification: Uncoated, round, biconvex, white to light creamy tablets, with a groove on one surface.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Volitamisolek:

Licence status A

Loa andmise kuupäev:

2014-08-14